What’s Going On With Mullen Automotive Stock Thursday?

Mullen Automotive Inc (NASDAQ: MULN) shares are trading higher Thursday. The company announced that Class 3 vehicle production has begun. 

Mullen Automotive Inc (NASDAQ:MULN) shares are trading higher Thursday. The company announced that Class 3 vehicle production has begun. 

What To Know: Mullen said it started production of the Mullen THREE Class 3 EV truck at its Tunica, Mississippi assembly plant. The first customer deliveries are expected to begin in “August and September.”

Mullen expects to ramp production gradually from September to December. Once fully ramped, the company anticipates production of 3,000 Class 3 vehicles per year at the plant. 

“I am proud to announce that our Class 3 vehicle line is now in production mode at our Tunica facility. Our team has been working seven days a week, day and night, getting this plant reconfigured and ready for Class 3 production,” said David Michery, chairman and CEO of Mullen.

Mullen noted that it has received purchase orders for 1,250 Mullen THREE trucks valued at $79 million. The purchase orders came from Randy Marion Automotive Group and MGT Lease Company.

See Also: Why Innoviz Stock Is Tumbling Today

MULN Price Action: Mullen shares were up 6.1% at 12 cents at the time of publication, according to Benzinga Pro.

Photo: courtesy of Mullen.

Total
0
Shares
Related Posts
Read More

LOBO EV Expands E-Bike Production Capacity With New Facility In Wuxi, China; Assembly Lines At The New Facility Are Projected To Support An Annual Production Exceeding $27M In Value, Boosting LOBO’s Manufacturing Output

LOBO EV Technologies Ltd. (NASDAQ:LOBO) ("LOBO" or the "Company"), an innovative electric vehicle manufacturer and seller, today announced the opening of its new 135,754-square-foot manufacturing facility in Wuxi, China.

LOBO

Read More

Sorrento Announces Arbitrator In Nantcell/NANTibody Arbitration Issued Award Granting Contractual Damages, Pre-award Interest Of $156.8M To Nantcell; Award Also Held That Co Has No Further Obligations Under Exclusive License Agreement With NANTibody

As previously disclosed, Sorrento Therapeutics, Inc. (“Sorrento” or the “Company”) has been engaged in arbitration before the American Arbitration Association against NantCell, Inc.

SRNE